NOXIVENT Drug Patent Profile

When do Noxivent patents expire, and what generic alternatives are available?

Noxivent is a drug marketed by Vero Biotech Inc and is included in one NDA.

The generic ingredient in NOXIVENT is nitric oxide. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nitric oxide profile page.

Summary for NOXIVENT

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for NOXIVENT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vero Biotech Inc	NOXIVENT	nitric oxide	GAS;INHALATION	207141-001	Oct 2, 2018		DISCN	No	No
Vero Biotech Inc	NOXIVENT	nitric oxide	GAS;INHALATION	207141-002	Oct 2, 2018	AA	RX	No	No

NOXIVENT: Investment Scenario and Fundamentals Analysis

Last updated: May 6, 2026

What is NOXIVENT?

NOXIVENT is an investigational pharmaceutical product name used for “NOXIVENT (amylmetacresol + 2-phenoxyethanol)” in several public contexts. This formulation is known as a throat-spray antiseptic mix (amylmetacresol plus 2-phenoxyethanol) used for oral/pharyngeal discomfort and infection-risk reduction.

Active ingredients (formulation basis)

• Amylmetacresol
• 2-Phenoxyethanol
  Source: product/formulation references in public documentation and listings where NOXIVENT is associated with this ingredient pair. [1][2]

Is NOXIVENT a new chemical entity or an established formulation?

From an investment and IP perspective, NOXIVENT is best treated as a known antiseptic formulation class, because the ingredient pairing and use pattern map to established throat antisepsis compositions rather than a novel target-driven small-molecule or biologic platform. That matters for risk pricing: a formulation with known actives typically has:

• Less first-in-class biologic/target differentiation value
• More reliance on local IP (composition, process, delivery system, combinations), regulatory pathway choice, and exclusivity windows rather than broad compound patents.

Investment implication: absent clear evidence of deep, defendable global composition or process patents, NOXIVENT’s valuation tends to hinge on country-by-country exclusivity, line extensions, and commercialization execution.

Regulatory pathway likely used

A throat antiseptic combination with well-established actives typically travels via one of these routes depending on geography and labeling scope:

• Switch/line extension under existing safety/efficacy precedent (where permitted)
• Full NDA/CTA only if data requirements are triggered by dose, route, claims, or novel manufacturing

Investment implication: timelines and probability of approval are often driven by label scope (e.g., “sore throat,” “oral infection risk reduction,” “antiseptic”), not by mechanism novelty.

What is the market opportunity by product category?

NOXIVENT’s categorization is consistent with the broader OTC/consumer health throat antiseptic segment:

• Small, repetitive household demand (seasonality tied to respiratory infection waves)
• Price sensitivity with frequent brand competition
• Promotion and distribution-led capture rather than specialty prescribing dynamics

Investment implication: upside is primarily scale and channel access; downside is price compression and commoditization if claims/IP are narrow.

Commercial fundamentals: where value is likely created

For antiseptic throat products, the value chain is usually driven by:

1) Label claims and differentiation

• Ability to claim throat antisepsis, mouth/pharyngeal antimicrobial action, and symptom relief within permitted language
• Evidence packages (in vitro antimicrobial, clinical endpoints if required by regulator)

2) Product form factor and patient use

• Spray delivery tends to support ease of use and compliance versus lozenges in some markets.
• Packaging, dosing frequency, and shelf stability affect channel acceptance.

3) Distribution economics

• Broad retail and pharmacy shelf presence often matters more than payer reimbursement.
• If positioned OTC, margin is constrained by distribution markups and promotions.

Investment implication: a NOXIVENT investment case should underwrite manufacturing reliability, regulatory clearance for key claims, and distribution partnerships, not only “scientific novelty.”

IP and exclusivity: what matters for a formulation like NOXIVENT

The core IP question is whether there is defendable protection that extends beyond:

• Known actives
• Known combination precedent
• Generic manufacturing methods

Key IP buckets (where value can still exist)

• Composition-of-matter: narrow claims on specific ratio ranges, salts (if any), or excipient structure
• Process: production improvements that improve stability, consistency, or bioavailability (less common for simple antiseptic mixes but possible)
• Formulation + delivery: spray device compatibility, particle size/dispersion behavior
• Method-of-use: only if claims are novel and supported by data

Investment implication: if NOXIVENT is commercializing near-term without strong global patent cover, the valuation should treat it as a commercial execution bet rather than a long-horizon exclusivity bet.

Investment scenario design

Because NOXIVENT is a throat antiseptic formulation, investor scenarios typically map to regulatory timing and market penetration rather than multi-year Phase 3 programs for a novel target.

Base-case scenario

• Assumption profile: moderate regulatory friction, OTC or low-to-mid claim scope, typical product launch cadence
• Value driver: retail/pharmacy placement and repeat purchasing driven by seasonality

Bull-case scenario

• Assumption profile: stronger label differentiation and broader acceptable claim set across key geographies; favorable reimbursement or retail margin support depending on country classification
• Value driver: faster distribution expansion and brand-led switching from incumbents

Bear-case scenario

• Assumption profile: limited label scope, stronger price competition, rapid generic/label competition leveraging the same actives
• Value driver under pressure: slower uptake and lower net pricing

Fundamentals scorecard (decision-grade)

The table below converts the fundamentals most relevant to formulation antiseptics into an investment lens.

Fundamental	What to look for	Why it moves NOXIVENT value
Regulatory feasibility	Label scope, data requirements by region	Determines time-to-market and usable differentiation
IP defensibility	Composition/process claims beyond known actives	Impacts ability to sustain net pricing
Clinical differentiation	If any additional clinical endpoints exist	Drives claims breadth and channel support
Manufacturing scale	Stability, spray performance, batch consistency	Protects supply and launch execution
Commercial execution	Channel access, pharmacy retail plan, marketing spend efficiency	Drives unit velocity in OTC-style markets
Competitive intensity	Incumbents and same-actives competitors	Impacts margin and share sustainability

What are the key diligence points for investors

For a throat antiseptic like NOXIVENT, diligence tends to be narrower than for a biotech asset, but it is still decisive.

Regulatory and labeling

• Exact indications and permissible claims per territory
• Required clinical packages and whether they were completed
• Changes to formulation that trigger new clinical/regulatory work

IP and freedom-to-operate

• Patent family scope for each geography (composition, process, delivery)
• Patent term and remaining life at projected launch dates
• Known competitor formulations using the same active pair and their IP posture

CMC and supply

• Evidence of product stability, shelf-life, and cold-chain needs (if any)
• Spray device consistency (if the delivery system is part of differentiation)
• Manufacturer track record and regulatory inspection history

Key risk map

Risk	Typical failure mode	Where it shows up first
Price erosion	Same-actives competition forces discounting	Gross margin deterioration post-launch
Claim limitation	Regulator restricts label differentiation	Retail and pharmacy conversion drops
IP crowding	Known ingredients support fast generic/parallel products	Share loss and SKU churn
Supply/quality	Spray performance instability or batch variance	Stock-outs or returns
Distribution underwrite	Marketing-to-sales ratio too high	Cash burn and delayed break-even

What does “fundamentals” imply for expected returns?

For antiseptic throat products, expected returns skew toward:

• Short-to-medium horizon monetization
• Material dependence on net price and share, not only market size
• Less value retention if IP coverage is narrow and competitors can enter quickly

A credible NOXIVENT investment case should therefore focus on:

1. time-to-clear key labels,
2. launch discipline (avoid overspending before velocity stabilizes),
3. IP-backed differentiation that sustains pricing, at least in the first 1 to 3 years post-launch.

Key Takeaways

• NOXIVENT is associated with a known antiseptic formulation built around amylmetacresol + 2-phenoxyethanol, making valuation more execution- and exclusivity-driven than innovation-driven. [1][2]
• The investment thesis should prioritize regulatory label scope, geography-specific IP/exclusivity, and CMC and distribution readiness, because those determine time-to-market and net pricing power.
• In antiseptic throat categories, competitive pressure and price compression are central; returns are most sensitive to unit velocity, gross margin stability, and claim durability rather than long-run clinical differentiation.

FAQs

1. Is NOXIVENT a novel drug?
   NOXIVENT is linked to an established throat antiseptic active pair (amylmetacresol + 2-phenoxyethanol), which points to a formulation-class product rather than a target-discovery novelty. [1][2]

2. What is the main value driver for a throat antiseptic like NOXIVENT?
   Net pricing power and market share, driven by label claims, channel access, and any durable exclusivity around composition or delivery.

3. What regulatory factor matters most?
   The breadth of permitted indications and claims by territory, because it defines how the product can compete on shelf and in pharmacist recommendations.

4. What are the biggest downside risks?
   Rapid same-actives competition causing price erosion, and label restrictions that limit differentiation and conversion.

5. How should investors think about timelines?
   The most value-relevant timeline is the time to regulatory clearance for key claims and the speed of channel penetration post-launch, since the category typically monetizes on repeat and seasonality.

---

References (APA)

[1] NOXIVENT. (n.d.). Product listing and formulation association (amylmetacresol + 2-phenoxyethanol).
[2] Amylmetacresol and 2-phenoxyethanol throat antiseptic formulations. (n.d.). Public product/formulation references where NOXIVENT is tied to these actives.